Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy
The Efficacy and Safety of Azacytidine Combined With HAG Regimen Versus Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy: a Prospective, Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Guangdong
-
Shenzhen, Guangdong, China, 518035
- Recruiting
- Shenzhen Second People's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 60;
- Patients with newly diagnoised diseases including MDS/AML/CMML;
- The ECOG behavior status score is less than 3 points;
- Agree to sign informed consent
Exclusion Criteria:
- Patients with a history of sever heart disease;
- Patients with severe organ dysfunction;
- Patients with other malignancies
- Patients who are allergic to the treatment of drug ingredients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Azacytidine + HAG Regimen
Azacytidine(75mg/m2 )+ HAG Regimen(Homoharringtonine(HHT) 1mg/(m2.d)
, Cytarabine 10mg/(m2.d),
G-CSF 200ug/(m2.d)
)
|
Azacytidine(75mg/m2 QD for 7 days)+ HAG Regimen(Homoharringtonine(HHT) 1mg/(m2.d)
for 14 days), Cytarabine 10mg/(m2.d)
for 14 days, granulocyte colony-stimulating factor(G-CSF) 200ug/(m2.d)
for 14 days until absolute neutrophil count(ANC) ≥ 10X109/L)
Other Names:
|
|
Active Comparator: Azacytidine
75mg/m2
|
Azacytidine 75mg/m2 QD for 7 days.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of Participants (Responders) Achieving Overall Response Rate(ORR) After the Fourth Cycle Treatments.
Time Frame: 4 months
|
4 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Bone Marrow Diseases
- Hematologic Diseases
- Myelodysplastic-Myeloproliferative Diseases
- Leukemia
- Leukemia, Myeloid
- Myelodysplastic Syndromes
- Leukemia, Myelomonocytic, Chronic
- Leukemia, Myelomonocytic, Juvenile
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Azacitidine
- Cytarabine
Other Study ID Numbers
Other Study ID Numbers
- 20190109
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.